

## TD2022IRMS version 1.0

### Summary of Major Modifications

The *Technical Document* on Detection of Synthetic Forms of *Prohibited Substances* by GC/C/IRMS, TD2022IRMS version 1.0, has been modified to include the following main changes:

- Prednisone (PS) and prednisolone (PSL) have been removed as target compounds (TCs) for GC/C/IRMS analysis. This decision has been triggered by the revised, higher *Minimum Reporting Levels (MRLs)* defined for these two glucocorticoids in the TD2022MRPL, which make GC/C/IRMS analysis unnecessary for reporting *Adverse Analytical Findings (AAFs)* at levels higher than (>) the *MRL*.

#### Articles 2.4 (Overall) Conclusion of GC/C/IRMS Findings

- Further clarifications are provided on the interpretation of GC/C/IRMS and the use of secondary Endogenous Reference Compounds (ERCs).

The TD2022IRMS version 1.0 replaces the former TD2021IRMS version 2.0 and becomes effective on 1 January 2022.